ANAPTYSBIO, INC. Income Taxes Paid
ANAPTYSBIO, INC. (ANAB) reported Income Taxes Paid of $44.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2025-11-04
- ANAPTYSBIO, INC. income taxes paid for the quarter ending 2025-09-30 was $0.00.
- ANAPTYSBIO, INC. income taxes paid for the quarter ending 2025-06-30 was $39.00K.
- ANAPTYSBIO, INC. income taxes paid for the quarter ending 2025-03-31 was $5.00K.
- ANAPTYSBIO, INC. income taxes paid for the quarter ending 2024-09-30 was $0.00.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $39.00K derived: sum of 2 quarters · filed 2025-11-04 | $44.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $44.00K 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $5.00K 10-Q · filed 2025-05-05 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |